Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models

Antibodies blocking the programmed death-ligand 1 (PD-L1) have shown impressive and durable responses in clinical studies. However, this type of immunotherapy is only effective in a subset of patients and not sufficient for rejection of all tumor types. In this study, we explored in two mouse tumor...

Descripció completa

Dades bibliogràfiques

Autors principals:	Heng Sheng Sow, Jiang Ren, Marcel Camps, Ferry Ossendorp, Peter ten Dijke
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2019-04-01
Col·lecció:	Cells
Matèries:	anti-PD-L1 mAb 1 LY364947 2 mouse syngeneic tumor models 3
Accés en línia:	https://www.mdpi.com/2073-4409/8/4/320
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!